Enliven Therapeutics, Inc. (ELVN) stock
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$46.85−0.77 (-1.62%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Enliven Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Enliven Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $89.15M, up 0.9% year over year. For fiscal 2025 it was $85.86M, up 6.3% from the year before. The highest annual figure on record is $85.86M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.86M | +6.3% |
| FY2024 | Dec 31, 2024 | $80.78M | +25.1% |
| FY2023 | Dec 31, 2023 | $64.57M | +108.2% |
| FY2022 | Dec 31, 2022 | $31.02M | -19.3% |
| FY2021 | Dec 31, 2021 | $38.44M | +19.6% |
| FY2020 | Dec 31, 2020 | $32.15M | +69.2% |
| FY2019 | Dec 31, 2019 | $19.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.00M | +34.9% |
| Q1 FY2026 | Mar 31, 2026 | $20.69M | -16.9% |
| Q4 FY2025 | Dec 31, 2025 | $21.25M | +2.5% |
| Q3 FY2025 | Sep 30, 2025 | $18.23M | -14.3% |
| Q2 FY2025 | Jun 30, 2025 | $21.49M | +14.2% |
| Q1 FY2025 | Mar 31, 2025 | $24.90M | +24.7% |
| Q4 FY2024 | Dec 31, 2024 | $20.72M | +15.7% |
| Q3 FY2024 | Sep 30, 2024 | $21.26M | +8.4% |
| Q2 FY2024 | Jun 30, 2024 | $18.83M | +24.0% |
| Q1 FY2024 | Mar 31, 2024 | $19.97M | +68.1% |
| Q4 FY2023 | Dec 31, 2023 | $17.91M | +118.4% |
| Q3 FY2023 | Sep 30, 2023 | $19.61M | +150.4% |
| Q2 FY2023 | Jun 30, 2023 | $15.18M | +91.3% |
| Q1 FY2023 | Mar 31, 2023 | $11.88M | +68.3% |
| Q4 FY2022 | Dec 31, 2022 | $8.20M | -24.5% |
| Q3 FY2022 | Sep 30, 2022 | $7.83M | -24.7% |
| Q2 FY2022 | Jun 30, 2022 | $7.94M | -21.2% |
| Q1 FY2022 | Mar 31, 2022 | $7.06M | -0.8% |
| Q4 FY2021 | Dec 31, 2021 | $10.86M | +21.2% |
| Q3 FY2021 | Sep 30, 2021 | $10.40M | +9.1% |
| Q2 FY2021 | Jun 30, 2021 | $10.07M | +28.0% |
| Q1 FY2021 | Mar 31, 2021 | $7.12M | +22.8% |
| Q4 FY2020 | Dec 31, 2020 | $8.96M | +50.8% |
| Q3 FY2020 | Sep 30, 2020 | $9.53M | +85.4% |
| Q2 FY2020 | Jun 30, 2020 | $7.87M | +80.2% |
| Q1 FY2020 | Mar 31, 2020 | $5.79M | +62.7% |
| Q4 FY2019 | Dec 31, 2019 | $5.94M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.14M | – |
| Q2 FY2019 | Jun 30, 2019 | $4.37M | – |
| Q1 FY2019 | Mar 31, 2019 | $3.56M | – |
See a number that looks wrong?